@article{ce91e601ac2343eebd56e4d1f797290e,
title = "Prevalence of and indications for antipsychotic use in Parkinson's disease",
abstract = "Background: The prevalence of patients with PD taking antipsychotics is unknown. Objective: To measure the prevalence of patients with PD taking antipsychotics. Methods: We used the medical records-linkage system of the Rochester Epidemiology Project to study the use of antipsychotic medication in all persons with Parkinson disease in Olmsted County, Minnesota on 1 January 2006. Results: There were 296 patients with PD in Olmsted County on 1 January 2006. The overall prevalence of antipsychotic use was 9.8% (29 of 296); 95.5% (28 of 29) of the patients had dementia when initiating antipsychotics. The most frequent indication (71.4%; 20 of 28) was psychosis or behavior threatening to the patient or others. Conclusions: The prevalence of antipsychotic use in patients with PD is lower than expected from previously reported cumulative incidences. Dementia is highly prevalent in those starting antipsychotics. Most of the patients on antipsychotics had a reasonable risk-benefit ratio for taking them.",
keywords = "Parkinson's disease, antipsychotics, dementia, prevalence",
author = "Bower, {James H.} and Grossardt, {Brandon R.} and Rocca, {Walter A.} and Rodolfo Savica",
note = "Funding Information: *Correspondence to: Dr. James Bower, Department of Neurology, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA; E-mail: bower.james@mayo.edu Funding agencies: This study was funded by a generous grant from the Parkinson{\textquoteright}s Foundation. It was also made possible using the resources of the Rochester Epidemiology Project, which is supported by the National Institute on Aging of the National Institutes of Health (R01AG034676). However, the content is solely the responsibility of the authors and does not necessarily represent the official views of the Parkinson{\textquoteright}s Foundation or the National Institutes of Health. Funding Information: Dr. Bower has been employed by the Department of Neurology, Mayo Clinic. Mr. Grossardt has been employed by the Department of Health Sciences Research, Mayo Clinic and supported by NIH R01-AG034676. Dr. Rocca has been employed by the Department of Health Sciences Research, Mayo Clinic and Supported by NIH AG034676 (Principal investigator), AG052425 (Principal investigator), AG006786 (Co-investigator), AG044170 (Co-director), and AG004875 (Co-investigator). Dr. Savica has been employed by the Department of Neurology, Mayo Clinic. Publisher Copyright: {\textcopyright} 2017 International Parkinson and Movement Disorder Society",
year = "2018",
month = feb,
doi = "10.1002/mds.27256",
language = "English (US)",
volume = "33",
pages = "325--328",
journal = "Movement Disorders",
issn = "0885-3185",
publisher = "John Wiley and Sons Inc.",
number = "2",
}